Muscle symptoms associated with statins:: A series of twenty patients

被引:25
作者
Soininen, K
Niemi, M
Kilkki, E
Strandberg, T
Kivistö, KT
机构
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany
[2] Dist Hosp Kuusankoski, Kuusankoski, Finland
[3] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland
[4] Univ Helsinki, Dept Med, Geriatr Clin, FIN-00014 Helsinki, Finland
关键词
D O I
10.1111/j.1742-7843.2006.pto_193.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to examine the clinical profile of statin-induced myalgia in patients with no apparent predisposing factors. Patients who reported muscle complaints that limited daily functioning during statin use were prospectively identified among the patients of Kuusankoski District Hospital and its catchment area, a population of about 100,000, between January 2003 and July 2004. Twenty patients in whom the muscle complaints were probably attributable to the use of a statin were included in this series. There were no cases of severe myopathy or rhabdomyolysis, and the highest creatine kinase value observed was only about 1900 U/l. Of the 18 patients that were evaluable for creatine kinase level, 5 (28%) did not exhibit elevation of creatine kinase and 6 (33%) showed a minor increase only. Following discontinuation of the statin, resolution of symptoms and normalisation of creatine kinase occurred in 11 of the 13 patients with elevated creatine kinase value as well as muscle complaints. Statins may cause clinically important muscle symptoms without inducing a marked creatine kinase elevation.
引用
收藏
页码:51 / 54
页数:4
相关论文
共 15 条
[1]   Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar? [J].
Christians, U ;
Jacobsen, W ;
Floren, LC .
PHARMACOLOGY & THERAPEUTICS, 1998, 80 (01) :1-34
[2]   New insights into the pharmacodynamic and pharmacokinetic properties of statins [J].
Corsini, A ;
Bellosta, S ;
Baetta, R ;
Fumagalli, R ;
Paoletti, R ;
Bernini, F .
PHARMACOLOGY & THERAPEUTICS, 1999, 84 (03) :413-428
[3]   The efficacy and six-week tolerability of Simvastatin 80 and 160 mg/day [J].
Davidson, MH ;
Stein, EA ;
Dujovne, CA ;
Hunninghake, DB ;
Weiss, SR ;
Knopp, RH ;
Illingworth, DR ;
Mitchel, YB ;
Melino, MR ;
Zupkis, RV ;
Dobrinska, MR ;
Amin, RD ;
Tobert, JA .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (01) :38-42
[4]   Effects of HMG-CoA reductase inhibitors on skeletal muscle - Are all statins the same? [J].
Evans, M ;
Rees, A .
DRUG SAFETY, 2002, 25 (09) :649-663
[5]   Lipid-lowering drugs and risk of myopathy:: A population based follow-up study [J].
Gaist, D ;
Rodríguez, LAG ;
Huerta, C ;
Hallas, J ;
Sindrup, SH .
EPIDEMIOLOGY, 2001, 12 (05) :565-569
[6]   Statin-associated myopathy [J].
Hamilton-Craig, I .
MEDICAL JOURNAL OF AUSTRALIA, 2001, 175 (09) :486-+
[7]   Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism [J].
Lang, JE ;
Wang, P ;
Glueck, CJ .
CLINICA CHIMICA ACTA, 1996, 254 (01) :85-92
[8]   Isoprenoids as mediators of the biological effects of statins [J].
Liao, JK .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (03) :285-288
[9]  
McKelvie Penelope A, 2002, J Clin Neuromuscul Dis, V3, P143, DOI 10.1097/00131402-200206000-00002
[10]   Rhabdomyolysis and HMG-CoA reductase inhibitors [J].
Omar, MA ;
Wilson, JP ;
Cox, TS .
ANNALS OF PHARMACOTHERAPY, 2001, 35 (09) :1096-1107